The new ADP receptor antagonists significantly reduce deaths and cardiovascular morbidity compared with clopidogrel in patients with stable angina or acute coronary syndrome managed invasively, a meta-analysis has shown. These benefits were achieved without a significant increase in bleeding complications. The researchers identified eight randomised clinical trials comparing the new ADP receptor antagonists (prasugrel, ticagrelor and cangrelor) with clopidogrel in a total of 67,851 patients with stable angina or acute coronary syndrome.